transformed cells and exert potent cytotoxic activity in the absence of prior antigenic sensitization. 1 NK cells are a phenotypically and functionally heterogeneous population distinguished by surface expression of CD56 and lack of T-cell antigens such as the CD3 pan-T-cell marker or the T-cell receptor (CD56
). CD56 is an isoform of the neural cell adhesion molecule with unknown function, but CD56 density marks the maturation status of NK cells such that CD56
bright NK cells differentiate into CD56 dim NK cells supporting a linear model of development between these subsets. 2 These subsets are functionally divided into a CD56 bright immunoregulatory population that predominate in secondary lymphoid tissue and produce cytokines (e.g., interferon-c, tumor necrosis factor-b, IL-10, IL-13, and granulocyte macrophage colonystimulating factor), and a CD56 dim cytotoxic population primarily in circulation. 3, 4 Subpopulations of the CD56 dim cells expressing the low-affinity Fc receptor, CD16, participate in antibody-dependent cell-mediated cytotoxicity. 5, 6 NK cells lyse target cells in the absence of major histocompatibility complex class I (MHC-I) expression, which is unique from cytotoxic T cells that require antigen presentation by MHC-I to become activated for killing. 7 However, NK cells do not function independently of MHC-I. In a process known as licensing, na€ ıve NK cells that engage MHC-I are "educated" to recognize self and remain quiescent while simultaneously becoming activated to lyse targets that lack or down regulate this expression. 8 Virally infected and transformed cells commonly down regulate MHC as a mechanism of immune evasion from cytotoxic T cells, and this "loss of self" renders them sensitive to killing by NK cells. 9 NK-cell function is tightly regulated by a combination of signals received via inhibitory and stimulatory receptors that recognize MHC-I and other surface ligands. 8, 10, 11 It is the net effect of complex signaling that determines whether NK cells become cytotoxic or remain quiescent. The killer immunoglobulin-like receptor (KIR), lectin NKG2 receptors, and natural cytotoxicity receptors are the main families of known NK cell receptors described. 12 KIRs interact with classic human leukocyte antigen (HLA) ligands (HLA-A, -B, -C) whereas NKG2 receptors interact with nonclassic HLA ligands (HLA-E). KIR and NKG2 each have subsets of stimulatory and inhibitory receptors; under normal physiologic conditions, the inhibitory signals prevail. It is not enough to remove the inhibitory signals to activate NK-cell killing, but rather activating receptors must also interact with their cognate ligand, which are generally only up regulated under conditions that stress the target cell. 1, 8, 12 With each NK cell expressing a different pattern of receptors, they can sense and react to subtle changes in the microenvironment. NK cells have gained significant traction in adoptive immunotherapy clinical trials due to their graft-versustumor effect without apparent harm of graft-versus-host disease (GVHD). 13, 14 NK cells are cytotoxic against a variety of solid-organ and hematologic malignancies in vitro, and IL-2 or IL-15 exposure has been shown to augment cytotoxicity against NK-resistant cell lines. 15 Early trials of autologous NK cells lacked clinically efficacy, 16 presumably due to inhibition by self-MHC, and current immunotherapy is focused on allogeneic sources. Mismatch of KIR-HLA ligands, whereby the recipient is missing the cognate ligand to an inhibitory KIR on the donor cells, has been shown to enhance alloreactivity and graft-versusleukemia in vitro and in vivo. 17, 18 The greatest clinical benefit for allogeneic NK cells has thus far been demonstrated in patients with acute myelogenous leukemia (AML), including as salvage therapy for relapsed or refractory disease, [19] [20] [21] consolidation therapy following hematopoietic cell transplant (HCT), 22, 23 and NK donor lymphocyte infusions for relapse or graft rejection. 24 Cytokine-induced memory-like NK cells have recently been described and show promising clinical efficacy in early trials. 25 One challenge of adoptive transfer is the generation of enough alloreactive NK cells to overcome suppressive or competing host factors that prevent in vivo NK-cell survival and expansion. 20 We previously reported our 6-year manufacturing experience generating fresh allogeneic NK cells for human infusion in clinical trials using two methods, CD3 cell depletion (CD3 dep ) and CD3 cell depletion followed by CD56 cell enrichment (CD3 dep /CD56 enrich ). 26 Here, we review clinical-scale allogeneic NK-cell manufacturing under current good manufacturing practices (cGMPs) at our institution. Our current standard of CD3/CD19 cell depletion (CD3/CD19 dep ) effectively minimizes T-cell and B-cell contamination in a single manipulation that enriches for NK cells and accessory monocytes, and this is the largest report of their manufacturing for human infusion.
MATERIALS AND METHODS
Cell processing was performed between 2010 and 2015 at the Clinical Cell Therapy Laboratory housed within the Molecular and Cellular Therapeutics (MCT) cGMP facility at the University of Minnesota. 27 Institutional Review
Board approval was obtained for all clinical trials using NK-cell products supported by our facility as well as Food and Drug Administration (FDA) approval for investigational new drug status required for novel cellular therapies.
NK-cell processing
One day prior to infusion, mononuclear cells (MNCs) were collected from nonmobilized donor peripheral blood using a 15-L separation process on the (COBE Spectra Apheresis System (TerumoBCT)). All processing was performed in a closed system. T-cell and B-cell depletion was performed using the (Miltenyi Biotec CliniMACS cell selection system and reagents (Miltenyi Biotec)) according to the manufacturer's specification. Samples were sent for lot release testing prior to product release for infusion.
Product characterization
Samples sent for flow cytometry were processed in our Translational Therapy Lab where the cells were stained with a 4-color or 10-color panel, acquired on a (FACSCalibur (BD Biosciences) or LSR-II flow cytometer (BD Biosciences)), respectively, and analyzed using (FlowJo (FlowJo LLC)). The cells were characterized using antibodies against CD3, CD14, CD16, CD19, CD20, CD45, CD56, KIR, and NKG2A (BD Biosciences).
Lot release testing
Lot release testing included cell counts, purity, viability, Gram stain, and endotoxin. Patient dosages were based on cell counts obtained using a hematology analyzer (Coulter MD II, Beckman Coulter; Sysmex XS1000i, Sysmex America, Inc.) for nucleated cell (NC) dose (<8 3 10 7 /kg) and flow cytometry for T-cell dose (<3 3 10 5 CD3 1 cells/kg). NK-cell purity standards required adjustments throughout our manufacturing process. Purity was initially set at 20% or more (CD56 1 CD3
2 ) NK cells and increased to 30% or more upon recommendation by the FDA that the addition of CD19 cell depletion called for a higher threshold than was previously established for CD3 dep products. The specification was adjusted to a threefold increase in NK-cell percentage between the final product and the apheresis MNCs after two products did not meet 30% NK-cell purity due to low starting NK-cell content. Another product failure led to speculation of interference from nonspecific antibody binding and lymphocyte gating was added without further issue. Specification for B cells was set at <3% CD20 1 cells.
Viability testing was performed using flow cytometric analysis of 7-aminoactinomycin D (BD Biosciences) with a lot release specification of 70% or more. The Clinical Microbiology Laboratory carried out Gram staining by standard methods, and product release specification was no organisms identified. In-house endotoxin testing was performed using a validated chromogenic limulus amebocyte lysate-based endotoxin assay (Kinetic-QCL, Lonza) with release criteria of 5 EU/kg or less per total product. Mycoplasma testing was not required by the FDA because of closed-system processing and a brief culture time that did not include animal serum products. Sterility testing using a 14-day culture in an (automated BacT/ALERT microbial detection system (bioM erieux, Inc.) or BACTEC blood culture system (BD Biosciences)) was performed as postrelease testing but was not required for lot release.
Cytotoxicity testing
In vitro cytotoxicity using a 4-hour chromium release assay was tested against the NK-cell-sensitive K562 line as previously described. 28 Effector-to-target ratios were based on NC counts and ranged from 20:1 to 0.08:1.
Statistical analysis
The percentages of NK cells and other continuous variables were presented with mean 6 standard deviation (SD) for different groups. t test was used for comparisons between two groups. Linear regression model was used to compare cytotoxicity between the CD3/CD19 dep IL-2 activated and IL-15 activated groups, adjusting for their baseline level. Bar charts with mean and standard error (SE) of the mean were presented for NK-cell subsets and receptor profiles. Mean cytotoxicity was presented in line charts for different unstimulated and cytokine-activated NK-cell products, at different effector-to-target ratio levels. All tests were two-sided. p values less than 0.05 were considered statistically significant. All analyses were performed with (SAS 9.4 (SAS Institute)).
RESULTS
Since 2010, the MCT facility has manufactured over 100 CD3/CD19 dep NK-cell products from nonmobilized peripheral Briefly, we manufactured 57 CD3 dep NK-cell products and reported on 37 products that were not part of a dose escalation trial. Likewise, 13 products underwent a twostep manipulation of CD3 dep /CD56 enrich . Cell processing was similar among all three manufacturing methods with the following exceptions (see Fig. 1 ): 1) apheresis collection time was 3 hours for CD3 dep and 5 hours for subsequent processing; 2) (Depletion 1.1 software (Miltenyi Biotec)) used for CD3 dep was upgraded to Depletion 2.1 software for subsequent processing; 3) the unmanipulated MNCs from the CD3 dep /CD56 enrich products were held overnight at room temperature and processed the day after collection because of the lengthier two-step process, whereas all other products were processed on the day of MNC collection; 4) Enrichment 1.1 software was used for the CD56 positive selection; and 5) all products were incubated overnight in IL-2 except for the most recently manufactured CD3/CD19 dep NK cells, which were incubated in IL-15.
Comparative processing results are summarized in Table 1 2 ). There was a relative enrichment of CD14 1 monocytes As expected, the addition of CD56 enrichment resulted in highly purified NK cells (90 6 7% NK cells, 5% monocytes, 0.6% B cells, 0.2% T cells) with the greatest log reduction of T cells (4.3, p < 0.001 when compared to CD3/CD19 dep ). However, there was considerable cell loss in the two-step manipulation and NK-cell recovery was significantly compromised (19% vs. 74%, p < 0.001). Furthermore, the CD56
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2 NK cell purity decreased to 75% following overnight IL-2 incubation and the T-cell content increased to 1% (data not shown ). Cell processing from a single apheresis yielded a mean NK-cell dosage of 2 (range, 1.0-6.2) 3 10 7 cells/kg with only seven products requiring dose adjustments to be within lot release limits for infusion (one for NC dose and six for Tcell dose). All products have passed NK-cell purity testing since modification of the lot release specification as described in the lot release testing above. There was a mean 9.7-fold increase in CD56 Fig. 3B ), including KIR2DL1, KIR2DL2/ 3, or KIR3DL1, which are cognate ligands for HLA-C2, HLA-C1, HLA-BW4, respectively; 48% expressed inhibitory /kg for CD3/CD19 dep products, thus increasing the total number of NK cells available for infusion. k The cell processing time difference is attributed to concurrent cell depletion versus sequential depletion and enrichment. Cost includes cell processing supplies, lot release testing, and quality assurance review, with differences based on the number of columns and immunomagnetic bead reagents and technician time. Comparative cytotoxicity results summarized in Fig. 4 show that cytokine exposure enhanced the cytotoxicity of CD3 dep , CD3 dep /CD56 enrich , and CD3/CD19 dep NK-cells products over their unstimulated counterparts. The unstimulated CD3/CD19 dep cells had different baseline cytotoxicity between the IL-15 group (58% prior to cytokine activation) and the IL-2 group (47%) at 20:1 effector-totarget ratio (data not shown). After adjusting for the difference in baseline, the cytotoxicity of the IL-15-and IL-2-activated groups (73% and 62%, respectively, at 20:1 effector-to-target ratio) were not significantly different (p 5 0.77). The unstimulated CD3/CD19 dep NK cells in the IL-2 group had a limited data set for analysis (n 5 19 of the 66 products), and the true baseline cytotoxicity may not be representative.
It appears that baseline cytotoxicity of unstimulated products is enhanced with increasing absolute or relative monocyte content, with CD3 dep /CD56 enrich having the fewest monocytes (5%) and lowest baseline cytotoxicity (18% at 20:1 effector-to-target ratio), CD3 dep NK-cell products with 31% monocytes having intermediate baseline cytotoxicity (33%), and CD3/CD19 dep having the greatest number of monocytes (49%) and highest baseline cytotoxicity (54%). This may be a real phenomenon; however, caution should be exercised in comparative observation between manufacturing methods. The overnight hold of unmanipulated MNCs for the CD3 dep /CD56 enrich cohort prior to processing may have compromised their cytotoxic potential. In addition, effector-to-target ratios are based on NC count and the NK-cell content between manufacturing methods differ.
DISCUSSION
Adoptive immunotherapy using allogeneic NK cells for the treatment of malignancy with or without concurrent HCT is increasing as growing evidence supports a graftversus-tumor effect and protection against GVHD, graft rejection, and disease relapse. 13, 17, [29] [30] [31] [32] Over the past 15 years, the MCT facility has manufactured approximately 260 cGMP-grade NK-cell products from nonmobilized peripheral blood of related haploidentical donors in support of human Phase I and Phase II clinical trials. These cells have been used for the treatment of advanced solidorgan and hematologic malignancies, including breast and ovarian cancer, melanoma, renal cell carcinoma, Hodgkin lymphoma, and AML. 19, 20, 33, 34 We have demonstrated exportability with overnight shipping of processed NK cells and in-transit cytokine activation for infusion within 48 hours of apheresis collection. 35, 36 The first successful NK-cell adoptive immunotherapy trial at the University of Minnesota used CD3 dep ex vivo IL-2 activated NK cells as salvage therapy for poor prognostic cancers. 20 Remarkably, five of 19 patients with refractory and relapsed AML who received preconditioning with high-dose lymphodepleting chemotherapy achieved complete hematologic remission. Reduction in competing host lymphocytes inversely correlated with a rise in endogenous IL-15 and appeared to be prerequisite for donor NK-cell persistence and expansion. Dose escalation showed that infusion of 2 3 10 7 MNCs/kg was safe and a maximal tolerated dose was not reached. Transfusion-associated (TA)-GVHD was not observed at a mean T-cell dose of 2.1 (range, 0.5-6.5) 3 10 5 cells/kg.
However, two cases of passenger lymphocyte syndromeinduced hemolytic anemia 37 and one fatal case of lymphoproliferative disease secondary to reactivation of Epstein-Barr virus were observed. 20 To our knowledge these entities, caused by mature B-cell contamination and well known in the setting of solid organ and hematopoietic cell transplant, 38 had not been described previously in relation to NK-cell infusions. It was speculated that high-level purification with CD3 dep /CD56 enrich may reduce B-cell-related complications, improve T-cell depletion, and potentially enhance the immunotherapeutic efficacy of alloreactive NK cells. However, an improvement in purity proved to be at the expense of NK-cell recovery and was dually affected by cell loss from the two-step manipulation and procedural time logistics with an additional overnight hold of the apheresis MNCs prior to processing. These highly enriched products contained approximately one-third the NK-cell dose of CD3 dep products and failed to induce hematologic remissions. 19 Next-day processing may have had deleterious effects on NK-cell viability and functionality (cytotoxicity). Koehl and colleagues described significant NK-cell loss using the same CD56 enrichment method, albeit with better NK-cell recovery (41%, range, 14%-76%) than our experience (19%, range, 3%-38%). 39 In most cases, they performed CD3 depletion on the day of MNC collection, thus enriching for NK cells, monocytes, and B cells, followed by CD56 selection on Day 2. In some cases, two CD3-depleted products were pooled prior to CD56 selection. They noted that NK-cell recovery was more compromised in the exceptional instances where the MNCs were held overnight at 48C on a waver and processed on Day 2. They improved NK recovery to 68% (range, 40%-85%) in a cohort that underwent a faster method of CD3 depletion using newer Depletion 3.1 software (as opposed to Depletion 2.1 software), which was considerably less effective at T-cell reduction. Schaffer and colleagues evaluated haploidentical CD3 dep /CD56 enrich NK-cell infusions following lymphodepleting chemotherapy in patients with relapsed or progressive AML (n 5 6) or myelodysplastic syndrome (MDS, n 5 2) following HCT. 21 One adult patient with MDS and one pediatric patient with AML achieved a complete response, and a third adult patient with MDS had resolution of dysplastic features with persistence of the abnormal karyotype. The NK cells were completely processed on the day of MNC collection and infused the following day without in vitro cytokine incubation. The mean NKcell purity and recovery were 98.9% and 57.2% (range, 41.3%-86.8%), respectively. NK-cell dosages were 0.62 3 10 7 /kg in adult patients (n 5 4) and 1.86 3 10 7 /kg in pediatric patients (n 5 4). These results demonstrate the feasibility of this method and suggest that refinement of our protocol to minimize time from apheresis to processing may lead to better clinical outcomes. In another Phase I trial by Romee and coworkers, adoptive transfer of memory-like NK cells that were induced from CD3 dep / CD56 enrich NK cells using IL-12, IL-15, and IL-18 for relapsed and refractory AML has shown promising results. 25 In nine evaluable patients, the overall response rate and the complete remission rate (including incomplete blood count recovery) were 55% and 45%, respectively, with demonstration of NK-cell persistence and expansion in vivo. The optimal manufacturing method to maximize NKcell alloreactivity against tumor cell is ultimately not known and crosstalk between various hematopoietic cells and cytokines may be an important factor that is eliminated with high-level purification. In the setting of haploidentical HCT, graft manipulation with CD3/CD19 cell depletion is an alternative to highly purified CD34-selected grafts, which require "megadoses" of CD34 Thus, removal of accessory monocytes, which have a supporting role in NK-cell survival and function through direct cell-cell contact and humoral factors, 28 may be detrimental to optimal NK-cell processing. In addition, highlevel purification with the two-step depletion and selection process increases production cost and manufacturing time compared to single-step depletion. CD3/CD19 dep is a single-step manipulation that sufficiently reduces T-and B-cell contamination without compromising NK-cell recovery or depleting accessory monocytes. Clinical remissions have been demonstrated in patients with relapsed and refractory AML who received CD3/CD19 dep NK-cell infusions following lymphodepleting chemotherapy, and the remission rate was enhanced by targeted host T-regulatory-cell (Treg) depletion. 19 GVHD has not been observed with NK cells produced by any of our three manufacturing processes. T-cell depletion is standard practice to minimize the risk of TA-GVHD, a rare and fatal complication whereby mature donor T cells are alloreactive against host antigenpresenting tissues, particularly in the setting of immune suppression and haploidentical MHC mismatch. 43 Unlike HCT-associated GVHD, where engraftment protects the bone marrow compartment, TA-GVHD leads to bone marrow aplasia. Despite effective T-cell depletion with each of our manufacturing methods, a significant T-cell load is nonetheless infused in the final NK-cell product. Our lot release criteria for T-cell dose is a higher threshold than other reports showing GVHD occurrence at lower T-cell doses in the HCT setting, 44, 45 and significantly higher than what the FDA allots for transfusion of blood components. 46 Ablation of host antigen-presenting cells by alloreactive NK cells such that T-cell priming is prevented has been proposed as a mechanism of protection against GVHD by adoptively transferred NK cells. 8, 18 NK-cell receptors are under intense investigation for their graft-versus-tumor mediating effects. NK cells acquire KIR ligand expression as they go through education and licensing, and greater expression of inhibitory receptors leads to greater cytotoxic potential in the absence of their cognate ligand and in the presence of activating signals. 47 Thus, KIR-positive subsets are thought to be more functionally active than KIR-negative subsets. Ex vivo cytokine incubation has been shown to induce activating NK-cell receptors, although we have not evaluated for up regulation of these receptors in our NK cells with overnight cytokine incubation. 39 The majority of our NK cells had a CD56 dim CD16 1 phenotype, which is consistent with the major subset of circulating NK cells known for their cytolytic function, and expressed at least one inhibitory KIR or inhibitory NKG2A, or both. Given the high expression of CD16 on CD56 dim NK cells, antibodies such as rituximab may be synergistic with NK-cell therapy through antibody-dependent cellular cytotoxicity. 48 Likewise, antibody blockage of NKG2A or other inhibitory KIRs may augment cytolytic effects by blocking interaction with the cognate ligand. 49 
CONCLUSION
Optimization and standardization of NK-cell manufacturing is a clinical necessity to maximize reproducible antitumor effectiveness while minimizing toxicity. We are consistent in producing clinical-scale, cGMP-grade allogeneic NK cells from peripheral blood MNCs without the use of ex vivo expansion or feeder cells. Advantages of a peripheral blood source include collection and processing in a closed system to minimize contamination and the ability to return to the donor should subsequent collection be needed. Our current practice standard of T-cell and Bcell removal through CD3 and CD19 depletion improves NK-cell recovery and conserves monocytes compared to our previous method of CD3 depletion followed by CD56 enrichment, which is more effective at T-cell removal. Ultimately, the optimal processing method may depend on the setting for which the cells are prepared. Further development of our process will depend on the continuing elucidation of basic NK-cell biology as well as ongoing clinical trial experience and outcomes.
